1 Cost-Effectiveness Of Culture-Based Versus Empirical Antibiotic Treatment For Hospitalized Adults With Community-Acquired Pneumonia In Indonesia: A Real-World Patient-Database Study.

2 Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia?

3 prognostic value of acute kidney injury in patients with community-acquired pneumonia

4 pressing issues of rational antibiotic therapy for inflammatory diseases of the lower respiratory tract in pediatric practice

5 dispersible formulation of amoxicillin in the treatment of non-severe community-acquired pneumonia in children

6 plasma transforming growth factor-β1 level in patients with severe community-acquired pneumonia and association with disease severity

7 characteristics of colon microbiocenosis in toddlers with community-acquired pneumonia associated with iron deficiency anemia

8 molecular characterization of macrolide resistance of a mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia

9 Incidence of childhood pneumonia and serotype and sequence-type distribution inStreptococcus pneumoniaeisolates in Japan

10 Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

11 The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort

12 The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials

13 Detection of Mycoplasma pneumoniae in Mexican children with community-acquired pneumonia: experience in a tertiary care hospital

14 Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

15 The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort

16 Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

17 The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort

18 The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials

19 Detection of Mycoplasma pneumoniae in Mexican children with community-acquired pneumonia: experience in a tertiary care hospital

20 [Multicenter study of human adenovirus infection in pediatric community-acquired pneumonia in China].

21 Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia.

22 Confounding by indication of the safety of de-escalation in community-acquired pneumonia: A simulation study embedded in a prospective cohort.

23 Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity.

24 Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity,

25 The Risk of Corticosteroids in Community-Acquired Pneumonia.

26 Evaluation of a PCR Assay for Detection of Streptococcus pneumoniae in Respiratory and Nonrespiratory Samples from Adults with Community-Acquired Pneumonia

27 Etiology of community-acquired pneumonia in 254 hospitalized children

28 Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization

29 Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity

30 Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina

31 New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

32 Evaluation of a Rapid Immunochromatographic Test for Detection of Streptococcus pneumoniae Antigen in Urine Samples from Adults with Community-Acquired Pneumonia

33 Etiology of Community-Acquired Pneumonia: Increased Microbiological Yield with New Diagnostic Methods

34 Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia

35 Usefulness of the Streptococcus pneumoniae Urinary Antigen Test in the Treatment of Community-Acquired Pneumonia

36 Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients

37 Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia

38 Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain

39 Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults

40 Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults

41 Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults

42 Usefulness of the Streptococcus pneumoniae urinary antigen test in the treatment of community-acquired pneumonia

43 The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia

44 The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia

45 interferon tiloron inductor usage in complex therapy at patients with community-acquired pneumonia

46 aetiological spectrum of severe community-acquired pneumonia in hiv-positive patients from pune, india

47 observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the cap burden of illness questionnaire

48 a questionnaire study of injections prescribed and dispensed for patients diagnosed with mild/moderate community-acquired pneumonia in mongolia

49 severe community-acquired pneumonia due to legionella pneumophila serogroup 6

50 acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia

51 etiology and cytokine expression in patients requiring mechanical ventilation due to severe community-acquired pneumonia

52 community-acquired pneumonia associated with cytomegalovirus persistence: prevalence and peculiarities of clinical course

53 inpatient treatment of community-acquired pneumonias with integrative medicine

54 step-down antibiotic therapy of community-acquired pneumonia in children with burdened allergologic history and concomitant allergic pathology: focus on cefpodoxime proxetil

55 Home management of mild to moderately severe community-acquired pneumonia: a randomised controlled trial

56 Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy

57 Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland

58 Incidence and characteristics of viral community-acquired pneumonia in adults

59 Community-Acquired Pneumonia

60 Quantitative detection of Streptococcus pneumoniae from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia

61 The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia

62 Etiology of Community-Acquired Pneumonia in Hospitalized School-Age Children: Evidence for High Prevalence of Viral Infections

63 Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

64 Viral community-acquired pneumonia in nonimmunocompromised adults

65 Clinical characteristics and outcomes of community-acquired pneumonia in western Saudi Arabia: A four-year retrospective analysis of medical records

66 Clinical and economic burden of community-acquired pneumonia among adults in Europe

67 The role of viruses in the aetiology of community-acquired pneumonia in adults

68 Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

69 Community-acquired pneumonia

Keyword Connections

Journals

Research Groups

Bibliographies